0001178913-21-001289.txt : 20210405 0001178913-21-001289.hdr.sgml : 20210405 20210405163042 ACCESSION NUMBER: 0001178913-21-001289 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210405 FILED AS OF DATE: 20210405 DATE AS OF CHANGE: 20210405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioLineRx Ltd. CENTRAL INDEX KEY: 0001498403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35223 FILM NUMBER: 21805764 BUSINESS ADDRESS: STREET 1: 2 HAMA-AYAN STREET STREET 2: MODI-IN TECHNOLOGY PARK CITY: MODI-IN STATE: L3 ZIP: 7177871 BUSINESS PHONE: 972-2-548-9100 MAIL ADDRESS: STREET 1: 2 HAMA-AYAN STREET STREET 2: MODI-IN TECHNOLOGY PARK CITY: MODI-IN STATE: L3 ZIP: 7177871 FORMER COMPANY: FORMER CONFORMED NAME: BioLineRX, Ltd. DATE OF NAME CHANGE: 20100805 6-K 1 zk2125850.htm 6-K

SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of April 2021

Commission file number: 001-35223
 
_______________________
 
BioLineRx Ltd.
(Translation of registrant’s name into English)
 
_______________________
 
2 HaMa’ayan Street
Modi’in 7177871, Israel
 (Address of Principal Executive Offices)
 
_______________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:        

Form 20-F ☒          Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
 
Further to its Current Report on Form 6-K dated February 26, 2021, the registrant announces the following results of its Extraordinary General Meeting of Shareholders (the “Meeting”) which was held on April 5, 2021 at 3:00 p.m. (Israel time):
 
In respect of Proposal 1 – The proposal regarding the amendment to Section 4.3 of the Company’s Compensation Policy for Executives and Directors, relating to Directors’ and Officers’ insurance, was approved by the required majority of shareholders who participated in the Meeting.
 
In respect of Proposal 2 –The proposal regarding the amendments to Sections 5.3 and 5.4 of the Company’s Compensation Policy for Executives and Directors, relating to differential compensation for a Board chairperson, was approved by the required majority of shareholders who participated in the Meeting.
 
In respect of Proposal 3 – The required majority of shareholders who participated in the Meeting voted to approve an equity compensation grant to Philip Serlin, the Company’s Chief Executive Officer.
 
This Form 6-K is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
BioLineRx Ltd.
 
 
 
By:
/s/ Philip A. Serlin
 
 
 
Philip A. Serlin
 
 
 
Chief Executive Officer
 
 
Dated: April 5, 2021